Overview

  • Product name
    Anti-VEGF Receptor 3 antibody, prediluted
    See all VEGF Receptor 3 primary antibodies
  • Description
    Rabbit polyclonal to VEGF Receptor 3, prediluted
  • Tested applications
    Suitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive)(Human) (C terminal)

  • Positive control
    • Placenta, or Breast carcinoma.
  • General notes
    The concentration of this prediluted antibody is 2 µg/ml.

Properties

Applications

Our Abpromise guarantee covers the use of ab15295 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
  • Application notes
    IHC-P: Ready-to-use for 10 min at RT.
    Perform heat mediated antigen retrieval before commencing with IHC staining protocol(boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at RT for 20 min).

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Receptor for VEGFC. Has a tyrosine-protein kinase activity.
    • Tissue specificity
      Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
    • Involvement in disease
      Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
      Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • Cellular localization
      Membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • EC 2.7.10.1 antibody
      • flt 4 antibody
      • FLT-4 antibody
      • FLT4 antibody
      • FLT41 antibody
      • Fms related tyrosine kinase 4 antibody
      • Fms-like tyrosine kinase 4 antibody
      • LMPH1A antibody
      • PCL antibody
      • Soluble VEGFR3 variant 1 antibody
      • Soluble VEGFR3 variant 2 antibody
      • Soluble VEGFR3 variant 3 antibody
      • Tyrosine protein kinase receptor FLT4 antibody
      • Tyrosine-protein kinase receptor FLT4 antibody
      • Vascular endothelial growth factor receptor 3 antibody
      • Vascular endothelial growth factor receptor 3 precursor antibody
      • VEGF R3 antibody
      • VEGFR 3 antibody
      • VEGFR-3 antibody
      • VEGFR3 antibody
      • VGFR3_HUMAN antibody
      see all

    Anti-VEGF Receptor 3 antibody, prediluted images

    • ab15295 staining VEGF Receptor in human placenta by Immunohistochemistry (FFPE-sections).
    • ab15295 staining VEGF Receptor in human placenta by Immunohistochemistry (FFPE-sections).

    References for Anti-VEGF Receptor 3 antibody, prediluted (ab15295)

    This product has been referenced in:
    • Linthicum FH  et al. The periductal channels of the endolymphatic duct, hydrodynamic implications. Otolaryngol Head Neck Surg 150:441-7 (2014). Human . Read more (PubMed: 24376120) »

    See 1 Publication for this product

    Product Wall

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step
    H2O2 as blocking agent for 10 minute(s) · Concentration: 3% · Temperature: 25°C
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: citrate pH6, 20 min at 100C
    Sample
    Human Tissue sections (Osteosarcoma, Breast Carcinoma)
    Specification
    Osteosarcoma, Breast Carcinoma
    Permeabilization
    No
    Fixative
    Formaldehyde
    Username

    Abcam user community

    Verified customer

    Submitted Feb 26 2015

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up